NIAID's Pother Over Procurement

Brian Behnke, Illustration Works The US Congress refused to authorize $250 million (US) intended to fund development of a second-generation anthrax vaccine this year because of a misunderstanding over the meaning of a single word, "procurement," according to Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID). But the administration did not reduce the agency's responsibilities for developing that vaccine or for boosting bioterrorism research, Fauci say

Written byJohn Dudley Miller
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The US Congress refused to authorize $250 million (US) intended to fund development of a second-generation anthrax vaccine this year because of a misunderstanding over the meaning of a single word, "procurement," according to Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID). But the administration did not reduce the agency's responsibilities for developing that vaccine or for boosting bioterrorism research, Fauci says.

That decision leaves NIAID scrambling for $250 million from somewhere else in its $3.7 billion budget to pay for the vaccine. "We may have to eat it," says Fauci. The Department of Health and Human Services may extract the quarter-billion from other HHS agencies, but that is unlikely, Fauci says.

The new vaccine is needed because the only federally licensed anthrax vaccine may be unsafe for very young children, elderly people, and those who are immunocompromised, according to NIAID.1 Nevertheless, the Bush administration ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies